Abstract:Background: Methotrexate cutaneous ulceration is a rare methotrexate complication, and has only been described in case reports and case series. Objective: To document patient characteristics, morphologic features, and mortality risk factors for methotrexate cutaneous ulceration. Methods: A systematic literature review of PubMed and Embase (last date 1 November 2021) was performed with data collected from case reports and case series. This study was limited to cases of cutaneous ulceration; presence of oral ulceration was collected from within these cases. Results: 114 cases (men = 57.9%, mean age = 61 years) of methotrexate cutaneous ulceration met inclusion criteria. Psoriasis (69.3%), rheumatoid arthritis (18.4%), and mycosis fungoides (6.1%) were the most common indications for methotrexate use. Morphologies included erosions localized to psoriatic plaques (33.3%), epidermal necrosis/necrolysis (35.1%), localized ulceration (16.7%), and skin-fold erosions (5.3%). Methotrexate dose preceding toxicity varied greatly; median 20 mg/week, interquartile range 15-40 mg/week, range 5-150 mg/week. Most patients had risk factors for serum toxicity (baseline renal dysfunction = 37.8%, concurrent NSAID use = 28.1%, inadequate folic acid use = 89.1%). Thirty percent of cases involved mistakenly high methotrexate doses. Fourteen patients (12%) died. Absence of folic acid use (69% vs. 100%, p value < 0.001), pancytopenia (33% vs. 86%, p value < 0.001), and renal dysfunction at presentation (47% vs. 92%, p value < 0.001) were associated with increased mortality. Limitations: Selection bias present due to abstraction from case reports and case series. Conclusion: Methotrexate cutaneous ulceration is commonly preceded by dosage mistakes, absence of folic acid supplementation, and concurrent use of nephrotoxic medications. Renal impairment, pancytopenia, and absence of folic acid supplementation are key risk factors for mortality from this adverse medication reaction. Providers should regularly monitor methotrexate dosing adherence, drug-drug interactions, and perform routine laboratory evaluation. Index of suspicion for this toxicity should remain high given the varied clinical presentation and high mortality.

Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester

Methotrexate for the Placenta in Situ in Advanced Abdominal Pregnancy: A Case of Remaining Intra-Abdominal Infection and Myelosuppression after Methotrexate Treatment

Systemic methotrexate (MTX) in early pregnancy: a retrospective study of a tertiary maternity hospital

Severe toxic effects of low-dose methotrexate treatment for placenta accreta in a patient with methylenetetrahydrofolate reductase mutations

[Single Methotrexate Chemotherapy for Low-Risk Gestational Trophoblastic Tumor].

[Pregnancy outcome after preconceptional exposure to methotrexate for ectopic pregnancy]

[Curative Effects and Influenced Factors of Primary Chemotherapy with Single-Agent Methotrexate on Low-Risk Gestational Trophoblastic Neoplasia].

Methotrexate: Use in the Post Dobbs v. Jackson Era

High Maternal Serum Estradiol in First Trimester of Multiple Pregnancy Contributes to Small for Gestational Age via DNMT1-Mediated CDKN1C Upregulation

Fetal proximal and distal limb anomalies following exposure to mycophenolate mofetil during pregnancy: A case report and review of the literature

The Safety of Oral Fluconazole During the First Trimester of Pregnancy: a Systematic Review and Meta‐analysis

Single-Dose Methotrexate for Treatment of Ectopic Pregnancy

Low-risk Gestational Trophoblastic Neoplastic Outcome after Primary Treatment with Low-Dose Methotrexate from 2005 to 2017

A Rare Case of Acute Methotrexate Toxicity Leading to Bone Marrow Suppression

Analysis of risk factors and treatment outcome following methotrexate therapy in ectopic pregnancy

First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations

Methotrexate Cutaneous Ulceration: A Systematic Review of Cases

Methotrexate impaired in-vivo matured mouse oocyte quality and the possible mechanisms

Treatment of Cesarean Scar and Cervical Pregnancies Using the Ovum Aspiration Set for Intrachorial Methotrexate Injection as a Conservative, Fertility-Preserving Procedure

Safety profile of methotrexate used off-label in ectopic pregnancy: an active monitoring study based on a Chinese hospital pharmacovigilance system

Methylenetetrahydrofolate reductase deficiency and low dietary folate increase embryonic delay and placental abnormalities in mice